Quantitative Visualization of the Interaction between Complement Component C1 and Immunoglobulin G: The Effect of CH1

Saeko Yanaka1,2, Shigetaka Nishiguchi1, Rina Yogo1,2

  • 1Exploratory Research Center on Life and Living Systems (ExCELLS), Institute for Molecular Science (IMS), National Institutes of Natural Sciences, 5-1 Higashiyama, Myodaiji, Okazaki 444-8787, Japan.

Insights

Researchers visualized how Immunoglobulin G (IgG) interacts with the C1 complex, revealing a secondary binding site on IgG. This discovery offers insights into the complement pathway and potential therapeutic antibody development.

Area of Science:

  • Immunology
  • Structural Biology
  • Biochemistry

Background:

  • Immunoglobulin G (IgG) has a modular structure crucial for antigen recognition and effector functions like complement-dependent cytotoxicity.
  • IgG self-assembles into hexameric rings on antigen-presenting membranes, initiating complement pathway activation via C1q binding.

Purpose of the Study:

  • To investigate the initial molecular interactions in the complement pathway.
  • To quantitatively visualize the binding dynamics between mouse IgG and the C1 complex (C1q, C1r, C1s) using high-speed atomic force microscopy.

Main Methods:

  • High-speed atomic force microscopy (HS-AFM) for quantitative visualization.
  • Study of interactions between mouse IgG2b and C1 complex.
  • Analysis of interactions between a CH1-deleted IgG2a variant and C1/C1q.

Main Results:

  • C1q within the C1 complex exhibits restricted internal motion.
  • The C1 complex demonstrates enhanced binding affinity to on-membrane IgG2b assemblages compared to C1q alone.
  • A 1:1 interaction was observed between C1/C1q and a CH1-deleted IgG2a variant, involving a cryptic secondary binding site on the CL domain.

Conclusions:

  • The restricted motion of C1q in the C1 complex and increased binding affinity to IgG assemblages are attributed to reduced conformational entropy loss.
  • A novel, antigen-independent binding interaction mediated by the CL domain of IgG was identified.
  • Findings provide a basis for developing novel therapeutic antibodies targeting the complement pathway.